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Abstract 
Aim: We describe futures of ICU admission, demographic characteristics, treatment and 
outcome for critically ill patients with laboratory-confirmed and suspected infection with the 
H1N1 virus admitted to the three different critical care departments in Turkey. 
Methods: Retrospective study of critically ill patients with 2009 influenza A(H1N1) at ICU. 
Demographic data, symptoms, comorbid conditions, and clinical outcomes were collected 
using a case report form.  
Results: Critical illness occurred in 61 patients admitted to an ICU with confirmed (n=45) or 
probable and suspected 2009 influenza A(H1N1). Patients were young (mean, 41.5 years), 
were female (54%). Fifty-six patients, required mechanical ventilation (14 invasive, 27 non-
invasive, 15 both) during the course of ICU. On admission, mean APACHE II score was 
18.7±6.3 and median PaO2/FIO2 was 127.9±70.4. 31 patients (50.8%) was die. There were no 
significant differences in baseline PaO2/FIO2 and ventilation strategies between survivors and 
nonsurvivors. Patients who survived were more likely to have NIMV use at the time of ad-
mission to the ICU. 
Conclusion: Critical illness from 2009 influenza A(H1N1) in ICU predominantly affects 
young patients with little major comorbidity and had a high case-fatality rate. NIMV could be 
used in 2009 influenza A (H1N1) infection-related hypoxemic respiratory failure. 
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INTRODUCTION 
In 2009, cases of influenza like illness were first 
reported  in  Mexico  on  March  18;  the  outbreak  was 
subsequently confirmed as H1N1 influenza. A Novel 
H1N1  swine  origin  influenza  virus  has  led  to  a 
worldwide pandemic (1). In the affected patients, a 
novel swine origin influenza A (H1N1) virus (S-OIV) 
with molecular features of North American and Eur-
asian swine, avian, and human influenza viruses were 
isolated  (2).  In  the  same  month,  the  World  Health 
Organization (WHO) classified the global spread of 
this  virus  as  a  public  health  event  of  international 
concern.  After  documentation  of  human  to  human 
transmission of the virus in at least three countries of 
two  WHO  regions,  the  WHO  raised  the  pandemic Int. J. Med. Sci. 2011, 8 
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level to 6 (3). It has spread very rapidly since the first 
cases were diagnosed in Mexico with the subsequent 
spread  of  the  virus  throughout  Europe  during  the 
winter  season.  The  H1N1  2009  influenza  pandemic 
(pH1N1) has resulted in over 15921 deaths worldwide 
more than 212 countries as of 14 February 2010 (4). 
Turkey reported its first laboratory-confirmed case of 
influenza A (H1N1) on 16 May 2009, becoming the 
eighteenth country in the WHO European region to 
do so, and a second case on 17 May 2009 (5). 
The clinical picture in severe cases of pandemic 
(H1N1) 2009 influenza is markedly different from the 
disease  pattern  seen  during  epidemics  of  seasonal 
influenza, in that many of those affected were previ-
ously healthy young people. Current predictions es-
timate that, during a pandemic wave, 12-30 % of the 
population will develop clinical influenza (compared 
with 5-15% for seasonal influenza) with 4% of those 
patients requiring hospital admissions and one in five 
requiring critical care (6). 
Pandemic Influenza A (H1N1) virus infection is 
the first pandemic in which intensive care units (ICU) 
play a fundamental role. During the pandemic, a sig-
nificant number of patients became critically ill pri-
marily  because  of  respiratory  failure.  Most  of  these 
patients required intubation and mechanical ventila-
tion (7). 
In this report, we describe futures of intensive 
care  unit  admission,  demographic  characteristics, 
treatment and outcome for critically ill patients with 
laboratory-confirmed  and  suspected  infection  with 
the H1N1 virus admitted to the three different critical 
care departments during winter of 2009 in Turkey. 
MATERIAL AND METHODS 
In response to an outbreak of influenza A virus 
infection in Mexico, Turkish Ministry of Health de-
veloped a case report form. The patients were admit-
ted to hospital and critical care units according to this 
case report form. Data were collected retrospectively 
on all patients who had influenza A 2009 related crit-
ical  illness  from  November  1  2009  to  December  15 
2009. Ethical approval was provided from the Ethics 
Committee  of  Meram  Medical  Faculty,  Selcuk  Uni-
versity, Konya, Turkey. 
Influenza-like  illness  (ILI)  is  defined  as  fever, 
cough, and headache, accompanied by one or more of 
the following signs or symptoms: rhinorrhea, coryza, 
arthralgia,  myalgia,  prostration,  odynophagia,  chest 
pain, abdominal pain, and nasal congestion.  
Data were reported by the attending physicians 
reviewing medical charts,  radiologic and  laboratory 
records.  The  following  information  was  recorded; 
demographic  data,  comorbidities,  time  from  illness 
onset to hospital admission, time to first dose of anti-
viral delivery, microbiologic findings, and chest radi-
ologic  findings  at  ICU  admission.  Intubation  and 
mechanical ventilation requirements, adverse events 
during ICU stay and laboratory findings at ICU ad-
mission were also recorded.  
We classified patients according to case defini-
tions (confirmed, probable, or suspected) developed 
by  the  World  Health  Organization  and  Centers  for 
Disease Control and Prevention. A confirmed case of 
novel influenza A (H1N1) virus infection is defined as 
a person with an ILI with laboratory confirmed novel 
influenza  A  (H1N1)  virus  infection  by  real  time 
RT-PCR (8, 9).  
We defined critically ill patients as those admit-
ted  to  an  adult  intensive  care  unit  (ICU);  requiring 
mechanical ventilation or receiving intravenous infu-
sion of inotropic or vasopressors during the hospital-
ization. Severity of illness was assessed in adults us-
ing the Acute Physiology and Chronic Health Evalu-
ation (APACHE) II within 24 hours of ICU admission. 
We recorded co-morbidities and prior defined major 
co-morbidities as the presence of one or more of the 
following chronic medical conditions: asthma, chronic 
obstructive  pulmonary  diseases  (COPD),  congestive 
heart  failure,  malignancy,  neuromuscular  disorders, 
cerebral palsy, diabetes mellitus, coronary artery dis-
eases,  heart  diseases,  chemotherapy,  malnutrition, 
immunosuppressive status or renal failure. 
Nasopharyngeal-swab specimens were collected 
at  admission,  and  bronchial-aspirate  samples  were 
obtained  after  tracheal  intubation.  Specimens  were 
placed in transport medium and kept at a temperature 
from 2 to 4°C. RT-PCR testing was done in accordance 
with published guidelines from the U.S. Centers for 
Disease Control and Prevention (CDC) (10). Seasonal 
vaccination  history  and  radiographic  findings  were 
recorded to study form. Specimens (bronchoalveolar 
lavage  and  blood)  for  culture  sent  to  microbiology 
laboratory for detection of bacterial infection in inva-
sive  and  noninvasive  mechanically  ventilated  pa-
tients.  The  body-mass  index  (BMI,  weight  in  kilo-
grams divided by the square of the height in meters) 
was calculated. Obesity defined as a BMI 30 to 40 in 
patients. Morbid obesity defined as BMI > 40.  
Statistical analysis; Descriptive analysis included 
frequency (%) and mean ± standard deviation (SD). 
Mann-Whitney Test used for significance in between 
groups. We accepted P value <0.05 for significance. 
RESULTS 
During the study period which is November 1 
2009  to  December  15  2009,  61  critically  ill  patients 
were admitted to three different critical care units in Int. J. Med. Sci. 2011, 8 
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Turkey  due  to  confirmed  or  suspected  influenza  A 
2009 (H1N1) infection were assessed. In 45 patients, 
diagnosis was confirmed by real-time PCR for pan-
demic H1N1 virus. In 16 patients, diagnosis was sus-
pected  according  to  CDC  and  WHO  criteria  (8,  9). 
Average age was 41.52 ± 15.7 years and, 54 % were 
female (female: 33, male: 28). Mortality rate was 50.8 
% (31 patients). Mortality rate in males was 64.3% and 
in females 39.4% (p >0.05) Clinical characteristics of 
patients with influenza A virus infection were showed 
in Table 1, Table 2 and Table 3. In Table 4 comparison 
between survivors and nonsurvivors were shown. 
 
Table 1. Characteristics of the patients with Influenza A (H1N1) virus in critical care unit 
Variable   Value (mean±SD) 
Female sex, n(%)  33 (54.1) 
Age  41.52±15.7 
Physical examination   
 Respiratory rate   34.3±10.2 
 Mean arterial blood pressure   90.3±18.3 
 Heart rate  113.2±19.4 
Obesity, n (%)  17 (27.9%) 
 BMI, 30 to 40  13 (21.3%) 
 BMI, >40   4(6.6%) 
Underlying diseases, n (%)   
 Asthma  5 (8.1%) 
 COPD  9 (14.7%) 
 Pregnancy  3 (4.9%) 
 Neuromuscular   5 (8.1%) 
 Serebrovascular diseases  3 (4.9%) 
 Malignancy  6 (9.8%) 
 Arterial hypertension  8 (13.1%) 
 Diabetes mellitus  8 (13.1%) 
 Coronary artery diseases  5 (8.1%) 
 Chronic renal failure  6 (9.8%) 
 Immunosupression  4 (6.5%) 
 Chronic heart failure  7 (11.4%) 
 
Table 2. Laboratory findings of the patients with Influenza A (H1N1) virus in critical care unit 
Variable   Value (mean±SD) 
Laboratory findings   
 Leukocyte count, per mm3  8.73±6.95 
 Lymphocyte count, per mm3  0.76±0.57 
 Serum creatine kinase, U/L  418.7±529.1 
 Serum lactate dehydrogenase, U/L  604.8±316.9 
 Serum creatinin (mg/dL)  1.6±1.8 
 AST (U/L)  96.8±145.3 
 ALT (U/L)  45.6±70 
 Platelets count (per mm3)  188.8±108.4 
Opacity on initial chest X-ray, n (%)   
 Normal chest X-ray  2 (3.2%) 
 Bilateral infiltrates on chest X-ray  55 (90.1%) 
 1/4 quadrants infiltrates on chest X-ray   1 (1.7%) 
 2/4 quadrants infiltrates on chest X-ray  10 (17.2%) 
 3/4 quadrants infiltrates on chest X-ray  7 (12%) 
 4/4 quadrants infiltrates on chest X-ray  40 (69%) 
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Table 3. Clinical Course and Outcomes of Patients with Influenza A (H1N1) virus in critical care unit 
Variable   Value (mean±SD) 
APACHE II score  18.7±6.3 
Days from onset symptoms to ICU admission,   7.4±4.17 
Days from onset symptoms to first antiviral dose  7.09±4.24 
Mechanical ventilation on admission, n (%)   
 NIMV  42 (68.8%) 
 IMV, total n (%)  29 (45.9%) 
 IMV, on admission n (%)  14 (23%) 
 Intubation and IMV after NIMV  15(24.5%) 
Death n (%)  31(50.8%) 
The length of critical care stay (days)  8.4±5.68 
The length of hospital stay (days)  12.2±8.1 
NIMV: Noninvasive mechanical ventilation, IMV: Invasive mechanical ventilation 
Table 4. Comparison of survivors and nonsurvivors 
Patient characteristic  Survivors 
(n:30) (Mean±SD) 
Nonsurvivors 
(n:31) 
(Mean±SD) 
p value 
Age, years  38.2±12.9  44.1±17.7  ns 
Female sex, n (%)  20 (66.6)  13 (41.9)  ns 
Comorbidities, n (%)  26 (86.6)  24 (77.4)  ns 
BMI  28.1±5.3  27.4±8.5  ns 
Obesity, n (%)  10 (33.3)  7 (22.6)  ns 
APACHE II score  16.5±5.4  20.9±6.5  0.007 
PaO2 / FiO2 (mmHg)  136.6±75.7  120.1±65.6  ns 
Initial MAP (mmHg)  94.8±15.8  85.9±19.9  ns 
Days from onset symptoms to ICU admission,   7.73±4.29  7.39±3.96  ns 
Days from onset symptoms to first antiviral dose,   7.3±4.46  7.19±3.94  ns 
Mechanical ventilation on admission, n (%)       
 NIMV  25(83.3)  17(54.8)  0.016 
 IMV, total  8(26.7)  20(64.5)  0.003 
 IMV, on admission  1(3.3)  13(41.9)  0.0005 
 Intubation and IMV after NIMV  7(23.3)  8(25.8)  ns 
Duration of IMV  6.36±6.5  5.9±5.5  ns 
Duration of NIMV  4.0±3.4  3.3±3.8  ns 
Ventilation settings, (mean±SD)       
 Tidal volume per ideal body weight, mL/kg  6.6±1.3  6.4±1.2  ns 
 Plateau pressure. cmH2O  27.9±6.5  31.4±7.1  ns 
 Set PEEP, cmH2O  8.8±5.4  16.4±4.2  0.001 
Organ dysfunction       
 Creatinine, mg/dL  1.38±1.37  1.84±2.17  ns 
 AST, U/L  70.4±87.2  90.1±69.7  ns 
 Platelet count, 103/µL  193.1±87.2  185.0±125.9  ns 
 Bilirubin, mg/dL  0.85±0.90  1.06±0.97  ns 
Creatinin kinase, U/L  314.0±372.9  527.8±644.1  ns 
NIMV: Noninvasive mechanical ventilation, IMV: Invasive mechanical ventilation 
 
 
 Symptoms at presentation included fever (88.5 
%),  cough  (83.6  %),  sputum  (79  %)  and  dyspnea 
(96.7%).  Diarrhea,  nausea,  and  vomiting  were  re-
ported in 24.6 %, 39.3 %, and 45.9 %, respectively. The 
mean  time  from  the  onset  of  illness  to  critical  care 
admission was 7.56 ± 4.1 days (range, 2 to 22). Un-
derlying medical condition was existed in 50 (82 %) 
patients. Obesity (27.9 %) and COPD (14.7 %) were the 
most common conditions  in patients. There was no 
significant difference according to underlying medical 
condition  in  between  nonsurvivor  and  survivor 
groups. A total of 3 patients (4.9%) were pregnant, of Int. J. Med. Sci. 2011, 8 
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whom  2  had  another  underlying  medical  condition 
(asthma  and  heart  disease).  Of  the  4  pregnant  pa-
tients, 1 was in the first trimester, 1 was in the second 
trimester, 1 was in the third trimester, and 1 was in the 
postpartum period. 
 At the time of ICU admission, all patients had 
elevated lactate dehydrogenase levels (604.8 ± 316.9 
U/L), 25 (40.9 %) above 500 U/L, and 7 (11.4 %) above 
1000  U/L.  Thirty-three  patients  (54%)  had  elevated 
aspartate  aminotransferase  (144.5  ±  178.07  U/L). 
Thirteen  patients  had  elevated  alanine  aminotrans-
ferase (121.2 ± 127.5 U/L). Sixteen patients (26%) had 
increased creatinin kinase levels (mean 418.7 ± 529.1 
U/L) (range, 6 to 2573 U/L). C-reactive protein was 
measured in 48 patients (78.7%) with a mean of 95.1 ± 
49.5 mg/dL. Eighteen patients (24.6 %) had elevated 
creatinine levels (>1.2 mg/dL) at hospital admission. 
On admission, 11 of 61 (18 %) patients who were 
tested had leukopenia, 27 of 61 (42.2 %) had anemia, 
and 18 of 61 (29.5 %) had thrombocytopenia. Twelve 
of 61 patients had positive blood and bronchoalveolar 
lavage cultures. 
 Of the 61 patients, all of them received oselta-
mivir. The mean time from the onset of illness to the 
initiation  of  antiviral  therapy  was  7.4±4.17  days 
(range, 1 to 22 days); 2 of the patients received anti-
viral  therapy  within  48  hours  after  the  onset  of 
symptoms. Antiviral therapy was started before ad-
mission  in  4  patients,  on  admission  in  55  patients, 
within 48 hours after admission in 2 patients. There 
was significant difference according to the time from 
the onset of illness to the initiation of antiviral therapy 
between nonsurvivors and survivors (p<0.05). Initia-
tion time of antiviral treatment was earlier in survi-
vors compared to nonsurvivors. All patients received 
antibiotics. Antibiotic therapy was started before ad-
mission in 32 patients and on admission in 29 patients. 
Patients received a mean of two different antibiotics 
(range, one to five); 81% of the patients received more 
than  one  antibiotic.  Commonly  used  antibiotics  in-
cluded moxifloxacin (in 19 patients), linezolid (in 14 
patients), ampicilline-sulbactam (in 13 patients), clar-
ithromycin  (in  13  patients),  piperacillin-tazobactam 
(in 12 patients), imipenem (in 11 patients), third gen-
eration cephalosporin (in 9 patients), vancomycin (in 2 
patients), teicoplanin (in 4 patients), and tigecycline 
(in 8 patients).  
 Of  61  patients  for  whom  data  were  available 
regarding the  use of corticosteroids, 20 (32.8 %) re-
ceived intravenous steroids. Of the patients who re-
ceived corticosteroids, 85 % had an underlying med-
ical  condition;  the  most  common  conditions  were 
COPD and asthma (70%). Chest radiograph findings 
were abnormal in 55 patients. Radiographic findings 
including  bilateral  infiltrates  were  existed  in  55  pa-
tients  on  admission.  Patients  with  viral  primary 
pneumonia  had  bilateral  patchy  alveolar  opacities, 
affecting two or five quadrants in 51 patients.  
 All  patients  had  a  mean  oxygen  saturation  of 
65% (range, 45 to 80) in the absence of supplementary 
oxygen. After supplementary oxygen, all patients had 
a mean oxygen saturation of 83.7 % (range, 49 to 98).  
Mean APACHE II score was 18.7 ± 6.3 (range, 6 
to 37). All patients had gas exchange abnormalities on 
admission. PaO2/FiO2 ratio was 127.9±70.4 (range, 34 
to 420). ARDS was diagnosed in 48 patients (78.6 %) 
and ALI in 4 (6.5 %) of the patients. Clinical evidence 
of bacterial infection on ICU admission was present in 
7 patients (11.4 %).  
 Data on the use of mechanical ventilation in the 
ICU  were  available  for  all  patients.  Non-invasive 
mechanic  ventilation  was  performed  in  42  patients. 
Fifteen  of  these  patients  were  endotracheally  intu-
bated after a mean of 3.4 ± 1.7 days. Fourteen patients 
initially  received  invasive  mechanically  ventilation. 
Thirty  (49.2  %)  patients  survived  to  hospital  dis-
charge. APACHE II score was higher in nonsurvivors 
(20.9 ± 6.7) than survivors (16.5 ± 5.4) (p<0.01). There 
were 8 obese patients in nonsurvivor group and in 7 
obese patients in survival group (p>0.05). In 3th days, 
mean level of urea, creatinine, international normal-
ized ratio (INR) and heart rate were higher nonsur-
vivors  than  survivors  (p<0.05,  p<0.05,  p<0.05,  and 
p<0.01). PaO2/FiO2 ratio was lower in nonsurvivors 
than survivors in third ICU day (p<0.05). Renal failure 
began in third ICU day. Renal failure developed in 10 
patients and 6 of them died.  
Patients  divided  into  two  groups  according  to 
type  of  mechanical  ventilatory  support.  Of  all  pa-
tients, 56 (91%) were mechanically ventilated on the 
first day of ICU admission; 14 (23 %) patients received 
invasive and 42 (68.8 %) noninvasive mechanical ven-
tilation. Fifteen patients (24.5 %) who received non-
invasive ventilation ultimately required invasive ven-
tilation.  Full-face  mask  was  used  in  all  patients  for 
NIMV.  APACHE  II  score,  PCO2,  white  blood  cell 
count and neutrophil account were higher in invasive 
mechanical ventilation group than NIMV group. Ar-
terial  blood  pH  was  lower  in  invasive  mechanical 
ventilation  group  than  NIMV  group.  Duration  of 
NIMV and IMV were 5.28 ± 3.4 days (range, 2 to 14) 
and 6.92 ± 5.8 days (range, 1 to 19) respectively. In 
survivors, the length of invasive mechanical ventila-
tion  ranged  from  1  to  19  days  (6.2  ±  5.5days).  The 
length of NIMV ranged from 1 to 14 days (4.25 ± 3.8 
days). There were no significant differences in tidal 
volume  or  ventilation  strategies  between  survivors 
and nonsurvivors. Patients who survived were more Int. J. Med. Sci. 2011, 8 
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likely to have NIMV use at the time of admission to 
the ICU. Patients who died were more likely to have 
IMV use at the time of admission to ICU.   
DISCUSSION 
 Our data of critically ill patients with Influenza 
A  2009  (H1N1)  reveals  that  relatively  younger  pa-
tients are affected by the disease. Fever and respira-
tory symptoms were cardinal symptoms of disease in 
all patients. There was a relatively long period of ill-
ness prior to presentation to the hospital, followed by 
a short period of acute and severe respiratory deteri-
oration. These patients had severe hypoxia requiring 
high FiO2, PEEP, and ventilator pressures. Within 30 
days, 51% of critically ill patients had died. Previously 
published  reports  have  highlighted  cases  of  severe 
viral pneumonia affecting patients younger than the 
expected  age  of  patients  affected  during  a  normal 
influenza season (11). The low mean age is different 
from seasonal influenza, in which older patients ap-
pear  more  susceptible  to  severe  diseases  (12).  Our 
findings are consistent with these reports. In our data 
and  in  other  studies,  death  was  occurred  mostly 
young critically ill patients (1, 13, 14). But, the risk of 
death  increased  with  increasing  age.  Importantly, 
severity  of  illness  and  mortality  in  our  cohort  are 
similar  to  that  demonstrated  previously  with  novel 
H1N1. The first data from Mexico showed that most 
of  the  patients  were  previously  healthy  (1).  In  our 
study, the most of critically ill patients had comorbid-
ities and there was no difference according to comor-
bidities between survived and died patients. A history 
of  lung  diseases,  obesity,  diabetes,  hypertension, 
neurological diseases, malignancy, and heart diseases 
were  the  most  common  comorbidities  in  our  study 
(83.6%). Among critically ill patients, obesity has been 
shown to be a risk factor for increased morbidity, but 
not  consistently  with  mortality  (15).  In  our  study, 
there was no statistically significant difference due to 
obesity between survivors and nonsurvivors. We did 
not find a significant difference in BMI between sur-
vivors and nonsurvivors. An early 2009 meta-analysis 
indicated  that  obesity  was  not  associated  with  in-
creased  ICU  mortality  (16).  A  recent,  large  cohort 
study by Gong et al. (17) prior to 2009 novel H1N1 
infection, noted an association of obesity with ARDS 
but  not  with  mortality.  The  Canadian  novel  H1N1 
experience likewise suggests that BMI did not differ 
between  survivors  and  non-survivors  (18).  Patients 
with  H1N1  infection-related  critical  illness  experi-
enced  symptoms  for  an  average  of  6  days  prior  to 
hospital presentation, but rapidly worsened and re-
quired care in the ICU within 1 to 2 days (1). In our 
study, this duration was higher than other studies (1, 
18,  19).  The  tendency  of  females  to  develop  severe 
2009  influenza  A  (H1N1)  infection  in  this  series  is 
striking. A general female susceptibility has been ob-
served in other influenza case series of variable se-
verity including reports of H1N1 infections (18, 19). In 
this report, death was higher in males than females. 
The  explanation  for  increased  risk  of  death  among 
males in this report may be due to existence of more 
frequent comorbidities in man. In most of infectious 
diseases  and  related  conditions  such  as  sepsis  and 
septic shock, males represent a larger proportion of 
cases and have a higher mortality (20, 21). 
Importantly,  we  found  in  this  cohort  that 
APACHE II score may help to identify patients at high 
risk of death.  
Rarely, we used vasopressor support on day 1 
following ICU admission (3.2%). Broad-spectrum an-
tibacterial agents were initiated in almost all.  
Chest  radiographs  demonstrating  bilateral 
mixed interstitial or alveolar infiltrates were found in 
90% of patients.  
In our study, 92% of patients required ventilator 
support for profound hypoxemic respiratory failure, 
requiring high levels of inspired oxygen and PEEP. 
However, survival rate was higher in NIMV than in-
vasive ventilation. We used full-face mask in all pa-
tients  for  NIMV.  Noninvasive  ventilation  has  been 
used  an  alternative  therapy  for  patients  with  acute 
respiratory failure with hopes of obviating intubation 
and mechanical ventilation. The results of NIMV in 
hypoxemic respiratory failure have been conflicting, 
and the etiology of hypoxemia appears to be an im-
portant determinant  of its success. Ferrer et al. (22) 
compared NIMV to conventional venture oxygen de-
livery in patients with severe hypoxemic respiratory 
failure and found that NIMV decreased the need for 
intubation. This benefit was observed in the subgroup 
of  patients  with  pneumonia,  but  not  in  those  with 
ARDS, in which the intubation rates were high in both 
groups. A meta-analysis suggests that NIMV does not 
decrease  the  need  for  intubation,  so  there  is  not 
enough evidence to support its use in ARDS (23). Of 
all patients, 56 (91 %) were mechanically ventilated on 
the first day of ICU admission; 14 (23 %) invasively 
and 42 (68.8 %) noninvasively. Fifteen patients (24.5%) 
who  received  noninvasive  ventilation  ultimately  re-
quired invasive ventilation. Dominguez-Cherit et al. 
(24) reported that invasively ventilation was used in 
82.7%  of  patients.  In  Kumar’s  study  (18),  invasive 
ventilation was used in 81% of patients with swine flu 
associated respiratory failure. In our study, we used 
noninvasive ventilation in 68.8% of critically patients 
with 2009 Influenza A (H1N1) on admission ICU. In 
critically  ill  patients  with  2009  influenza  A  (H1N1) Int. J. Med. Sci. 2011, 8 
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infection,  high  levels  of  PEEP  were  often  used  to 
achieve adequate oxygenation. In our study, patients 
with ARDS were often had PEEP refractory hypox-
emia. It was also noted that once patients improved 
and  the  weaning  process  was  started,  oxygenation 
was sensitive to small decrements in PEEP. We used 
high PEEP levels up to 20-25 cmH2O in some patients.  
Use  of  noninvasive  mechanical  ventilation  has 
some  significant  problems  when  there  is  risk  of 
transmitting infectious diseases. Use of  noninvasive 
ventilation was identified as risk factor for transmit-
ting  infection  due  to  exposure  to  aerosols  during 
SARS epidemics (25). It was advised to avoid from 
noninvasive ventilation during SARS epidemic. These 
were expert opinions but in an experimental model, it 
was  claimed  that  noninvasive  ventilatory  support 
may increase occupational risk (26).  
However it was shown multiple times that non-
invasive ventilatory support may decrease mortality 
with avoiding from endotracheal intubation. It is dif-
ficult to identify immediately if patients are infected 
or not during epidemic so noninvasive ventilation can 
be  initial  chose  of  ventilatory  support  in  those  pa-
tients. There is always a potential harm from a with-
holding a procedure while there is epidemics. Even if 
there is risk to use noninvasive ventilation for H1N1 
patients since it may save the lives, we decided to use 
it  under  strict  isolation  including  negative  pressure 
isolation rooms. 
In conclusion, we have demonstrated that 2009 
influenza  A  (H1N1)  infection-related  critical  illness 
predominantly affects young patients with little major 
comorbidity and is associated with severe hypoxemic 
respiratory  failure,  often  requiring  prolonged  me-
chanical ventilation. Among patients admitted to ICU, 
older age, and a requirement for invasive ventilation 
were associated with increased risk of death, but be-
cause there were greater numbers of younger patients 
in  our  cohort,  the  majority  of  deaths  occurred  in 
younger patients. Alternatively, NIMV could be used 
in 2009 influenza A (H1N1) infection-related hypox-
emic respiratory failure. 
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